Dry Eye Clinical Trial - Azithromycin for Meibomian Gland Disease

Status Recruiting

Clinical Trial Summary

This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.

Clinical Trial Description

This is a randomized, placebo-controlled, double masked trial of the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction. Dry eye syndrome (DES) is a persistent feeling of ocular discomfort that encompasses dryness, irritation, foreign body sensation and burning. In the United States, it is the most common non-refractive cause of visits to eye care providers, and has been shown to have a significant impact on quality of life of patients who suffer from this condition. most common cause of DES is Meibomian gland disease (MGD). In the vast majority of cases, MGD is not binding, but rather causes persistant ocular discomfort. Oral antibiotics, particularly the tetracyclines and macrolides, are frequently prescribed for the treatment of MGD. There is little good-quality evidence to support this practice. This study is designed to evaluate the effectiveness of oral azithromycin on patient-reported dry eye symptoms. Concomitantly, we will also study the composition of the ocular surface microbiome in MGD, and its response for oral antibiotics. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03953118
Study type	Interventional
Source	University of California, San Francisco
Contact	Khashayar Nattagh, BA
Phone	19499107667
Email	khash.nattagh@ucsf.edu
Status	Recruiting
Phase	Phase 4
Start date	September 1, 2018
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05102409` - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease	Phase 2
Completed	`NCT05027087` - The Effect of a Novel Blueberry Supplement on Dry Eye Disease	Phase 3
Completed	`NCT06159569` - Performance and Tolerability of the Medical Device LACRIACT	N/A
Completed	`NCT04081610` - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution	Phase 1
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT03418727` - Dry Eye Disease Study With Brimonidine	Phase 2
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Recruiting	`NCT04527887` - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)	Phase 4
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT04553432` - Dry Eye OmniLenz Application of Omnigen Research Study	Phase 4
Recruiting	`NCT04109170` - Dry Eye Evaluation System Based on Bioinformatics
Completed	`NCT04105842` - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type	N/A
Completed	`NCT05505292` - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers	Phase 4
Completed	`NCT04668131` - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease	N/A
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Completed	`NCT02235259` - Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Phase 2
Not yet recruiting	`NCT02218827` - Topical Steroid Treatment For Dry Eye	N/A
Completed	`NCT01959854` - Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye	N/A